Wilex moves to CRO work; WuXi bags another regulatory nod;

> German biotech Wilex has effectively become a CRO after handing off its drug candidates and focusing on contract work to generate revenue. Story

> WuXi PharmaTech's ($WX) toxicology facility in Suzhou, China, has passed Belgian muster. More

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.